Allogene Therapeutics enters September with an unusual structural tension: Pfizer holds a 13D activist stake in the company while short sellers remain deeply dug in at more than a quarter of the free float.
The short side of the ledger is hard to ignore. Short interest is running at 26.3% of the free float — one of the highest readings in the clinical-stage cell therapy space — and has barely moved over the past month, down just 1.6%. That persistence says shorts have not been rattled by the stock's 5.6% one-month gain, and the week's 8.5% slide back toward $1.99 has done nothing to shake them out. The ORTEX short score of 70.0 ranks in the bottom 12th percentile of all stocks — meaning this name is flagged as more heavily shorted than roughly 88% of the market. That said, the borrow market itself is not generating much friction: cost to borrow is a nominal 0.51%, up 14% on the week but still far below anything that would create squeeze mechanics. Availability is ample at 261% — meaning more than two-and-a-half shares are available to lend for every share already borrowed — well above the 52-week tightest reading of 135%. Shorts are not paying up and are not being squeezed out.
Options positioning has shifted more cautiously this week. The put/call ratio climbed to 0.49, running about 1.5 standard deviations above its 20-day average of 0.34. That is a notable move higher, though the ratio remains far below its 52-week high of 1.27. The direction of travel matters more than the absolute level: the PCR spent most of August in a tight band between 0.31 and 0.38, then broke higher in the final days of the month. Options traders are adding defensive exposure into a stock that just gave back most of its August gain.
The most structurally interesting element of the ALLO register is Pfizer's position. Pfizer Inc. filed a Schedule 13D/A in February 2026, disclosing a 9% stake — and a 13D filing signals active intent, not passive holding. Pfizer Venture Investments holds 22 million shares, unchanged since at least June 30. That kind of strategic shareholder creates an unusual dynamic: a well-resourced holder with a stated active posture sits alongside short sellers who collectively own a comparable position in borrowed shares. The disclosure caveat applies — 13D/G stakes are event-driven filings around the 5% threshold, and the actual current position could differ from what was last reported. Still, a pharma giant with an active filing on a $2 cell therapy stock is one of the more distinctive facts on the cap table. Frazier Life Sciences also recently raised its disclosed stake to 5.6%, filing a 13G amendment on August 14, while BlackRock and State Street added material positions through July. Institutional accumulation has clearly been active in 2026.
The analyst picture is mixed and, at the headline level, stale — the formal consensus data is nearly seven weeks old. The most recent actionable note came from Citizens on August 17, where the firm reiterated its Market Outperform rating with a $6 target — below where several of ALLO's buy-rated analysts sit. Jefferies holds a $10 target and HC Wainwright a $11 after trimming from $12 in April. The mean price target of $9 implies roughly 350% upside from the current $1.99 price, which in clinical biotech reflects binary trial risk rather than a simple re-rating opportunity. The bull case rests on cema-cel's Phase 3 trial showing strong MRD-negativity rates in first-line DLBCL — a potential therapy benchmark if the data holds. Bears anchor to the $6 target and flag manufacturing risk, durability questions, and long-term dilution from the $175 million equity raise completed earlier in the year. The price-to-book multiple has climbed sharply over the past 30 days — up 1.46 turns to 2.69x — tracking the stock's partial recovery off its lows.
The most recent earnings print, on August 12, produced a one-day drop of 6.6% before recovering 5.2% over the following five days — a pattern that suggests the dip was bought. The next event is scheduled for November 5. Between now and then, the key variable is clinical data flow: the Phase 3 trial readout timeline and any interim updates will drive sentiment far more than any short-term positioning shift. The Pfizer 13D remains the single most watched structural fact on the register, and any amendment to that filing would immediately reset the narrative.
See the live data behind this article on ORTEX.
Open ALLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
